ULTRAGENYX CLASS ACTION LAWSUIT: A COMPLETE INVESTOR GUIDE [2026]
If you purchased or acquired shares of Ultragenyx stock between August 3, 2023 and December 26, 2025, and suffered a loss you are most likely a member of the class. Call Timothy L. Miles for more information about the lead plaintiff process or any other questions you may have at no charge. 855-846-6529 or [email protected]
Introduction to the Ultragenyx Class Action Lawsuit
- Who is Affected by the Ultragenyx class action lawsuit? All purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”).
- The Problem: The Ultragenyx class action lawsuit alleges the defendant made false and misleading statements driving the stock price artificially up until the truth emerged and the stock plummeted and shareholders who purchased during the relevant time period and suffered a loss are entitle to damages
- Your Action: You may be eligible to recover your losses in a Ultragenyx class action lawsuit
- Deadline to Lead: The deadline to apply to be Lead Plaintiff is April 6, 2026.
How it Works
- A lawsuit is initiated by one or more investors, called the “lead plaintiffs,” on behalf of a larger group of investors, or the “class”.
- The “class period” is defined as the specific timeframe during which the alleged fraudulent activity took place. Only those who bought or sold the security during this period are eligible to participate.
- A lead plaintiff is appointed to represent the class. Under the Private Securities Litigation Reform Act (PSLRA), the court will typically appoint the investor with the largest financial interest in the outcome of the case.
- The case is litigated, which may include a lengthy discovery phase for gathering evidence.
- The case can be settled or go to trial. Most class actions are resolved through settlements, which can include cash or stock paid into a common fund for the class. The lead plaintiff and class counsel approve any settlement before it is finalized.
Common Types of Misconduct
- Securities fraud class actions can arise from various types of misconduct by a company, its officers, or others involved in the sale of its securities, including:
- Making false or misleading statements in SEC filings, prospectuses, or earnings announcements.
- Overstating a company’s revenues or profits through fraudulent or “creative” accounting.
- Failing to disclose material information that would significantly alter an investor’s view.
- Engaging in market manipulation to artificially inflate or deflate a security’s price.
What Plaintiffs Must Prove
To succeed in a federal securities fraud class action, plaintiffs must prove several elements:
- Material misstatement or omission: The company made a false or misleading statement, or failed to disclose a material fact.
- Scienter: The defendant acted with an intent to deceive, manipulate, or defraud.
- Reliance: The plaintiff relied on the misstatement or omission when buying or selling the security. For publicly traded securities, this can be proven through the “fraud-on-the-market” theory, which presumes the market price reflects all public, material information.
- Economic loss: The plaintiff suffered a financial loss.
- Loss causation: The company’s misstatement or omission directly caused the plaintiff’s loss, often demonstrated by a stock price drop after the truth is revealed in a “corrective disclosure”
Benefits for Investors
- Participating in a class action allows investors to pool their resources, which offers leverage they would not have in an individual lawsuit against a large corporation.
- The collective approach also makes it more efficient and cost-effective to pursue legal action, especially for smaller investors.
How to Get Involved
- If you bought a security during the alleged class period and suffered a loss, you are generally automatically included in the class. You don’t have to take any action unless you want to file a claim for recovery later.
- You may be notified of a class action by mail if you are an eligible class member.
- You may be able to become a lead plaintiff by applying within 60 days of the first lawsuit being announced.
- If you believe you may have a claim, you can contact a securities class action law firm for guidance.
Allegations in the Ultragenyx Class Action Lawsuit
Ultragenyx is a biopharmaceutical company that focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases.
The Ultragenyx class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- Defendants created the false impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta (“OI”), while also minimizing risk that patients in Ultragenyx’ Phase III Orbit study would fail to achieve a statistically significant reduction in annualized fracture rate (“AFR”), such that the second interim analysis could be performed and presented to the investing public; and
- In truth, Ultragenyx’ optimism in the Phase III Orbit study’s results and interim analysis benchmark were misplaced because Ultragenyx failed to convey the risk associated with basing such threshold figures on Phase II results that had no placebo control group for appropriate comparison and thus had not ruled out that the reduction in AFR from that study could merely be triggered by an increased standard of care and the placebo effect of being provided a novel treatment.
The Ultragenyx class action lawsuit further alleges that on July 9, 2025, Ultragenyx revealed that the Phase III Orbit study failed to achieve statistical significance for the second interim analysis and that Phase III Orbit and Cosmic studies would now be “progressing toward final analysis.” On this news, the price of Ultragenyx stock fell more than 25%, according to the Ultragenyx class action lawsuit.
Then, on December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic Studies had not “achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively.” Ultragenyx allegedly attributed the study failure to a “low fracture rate in the placebo group” of Orbit and a trend that fell shy of statistical significance in Cosmic. On this news, the price of Ultragenyx stock fell more than 42%, according to the Ultragenyx class action lawsuit.
Options Available to Shareholders
- Do Nothing (Remain a Class Member): This is the most common option. If you take no action, you automatically remain a member of the class.
- Exclude Yourself (Opt-Out): You have the absolute right to exclude yourself from the class action. This is often referred to as “opting out.”
- How to Exclude Yourself (Opt-Out): The process for opting out is not available immediately, but only when the class has been formally certified and a settlement or trial is imminent.
- Wait for the Class Notice: If a settlement is reached, the court will approve a Notice of Proposed Settlement that is mailed to all known class members.
- Review the Notice: This document will contain specific, formal instructions on how to exclude yourself from the settlement.
- Submit a Written Request: You must draft and mail a letter stating clearly that you wish to be excluded from the class action, and include all identifying information (name, address, shares sold, etc.).
- Meet the Deadline: Your exclusion request must be postmarked by the deadline in the Notice.
Important Case Deadlines
Missing a court-mandated deadline can permanently forfeit your right to recover losses in a securities class action.
Our firm meticulously tracks every filing date, ensuring that all lead plaintiff motions and proof of claim forms are submitted accurately and on time.
If you purchased shares during the class period, you must act before the Lead Plaintiff Deadline to be considered for a leadership role in the case.
Contact our legal team today to verify the specific timeline for your active litigation and protect your status as a claimant.
Rights of Investors
Investors affected by the Ultragenyx class action lawsuit possess specific rights that they can exercise. Understanding these rights is vital for anyone considering involvement in the lawsuit.
Right to Information
- Investors have the right to receive accurate and timely updates regarding the Ultragenyx lawsuit.
- This includes information on the case’s progress, potential settlements, and any necessary actions they may need to undertake.
Right to Participate
- Affected investors have the right to join the Ultragenyx class action lawsuit.
- This allows them to collaborate with other investors in seeking compensation for their losses without the burden of filing individual lawsuits.
Right to Legal Representation
- Investors can seek legal counsel to navigate the complexities of the Ultragenyx class action lawsuit.
- Legal professionals can provide guidance and support throughout the process.
- If you suffered substantial losses and wish to serve as lead plaintiff of the Ultragenyx class action lawsuit or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected].
Contingency Fee Agreements: No Cost to Hire a Lawyer
- No Fee: It does not cost anything to hire a lawyer if you are eligible for a Ultragenyx class action lawsuit. We take all cases on a contingency basis which means we do not get paid unless we win or settle your case.
- Talk with a Lawyer Free of Charge: A lawyer can explain the process of a Ultragenyx class action lawsuit and answer any questions you may have free of charge.
Frequently Asked Questions About the Ultragenyx Class Action Lawsuit
What initiated the Ultragenyx class action lawsuit?
The Ultragenyx class action lawsuit is initiated by investors alleging that Ultragenyx provided misleading information regarding its financial health and operations, resulting in financial losses.
How can I join the Ultragenyx lawsuit?
If you purchased shares during the class period and suffered a loss, then you are automatically a member of the Ultragenyx class action lawsuit and do not need to do anything at this point unless you are considering moving for lead plaintiff.
What are the potential benefits of a Ultragenyx lawsuit?
Class action lawsuits like the Ultragenyx lawsuit allow individual investors to collectively seek justice and compensation, which might be challenging to pursue individually. They also promote corporate accountability.
How long will the Ultragenyx class action lawsuit take to resolve?
The duration of class action lawsuits can vary significantly, depending on the complexity of the case, legal strategies, and whether settlements are reached. It could take several months to years to resolve the lawsuit.
Contact Timothy L. Miles Today About a Ultragenyx Class Action Lawsuit
The most important thing you need to know is you can call me at no charge if you wish to serve as lead plaintiff of the Ultragenyx class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected]. (24/7/365).
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com
Facebook Linkedin Pinterest youtube
Visit Our Extensive Investor Hub: Learning for Informed Investors
